Please enable Javascript
Zachary Bessette
Zachary Bessette
Articles by Zachary Bessette
FDA Accepts New Drug Application for Prostate Cancer Imaging Agent
Zachary Bessette
Prostate Cancer Diagnostics
|
July 24, 2024
The FDA has accepted an NDA for TLX007-CDx, a cold kit for the preparation of PSMA-PET imaging for prostate cancer.
Read More
PSMA Tandem Treatment Offers Benefit for Patients With mCRPC
Zachary Bessette
RLT
|
June 11, 2024
A phase 3 trial offers the first randomized evidence of the benefit of PSMA tandem therapy in patients with mCRPC.
Read More
18F-rhPSMA-7 Versus Conventional Salvage Radiotherapy for BCR
Zachary Bessette
Prostate Cancer Diagnostics
|
June 11, 2024
New research provides evidence of 18F-rhPSMA-7 leading to more favorable disease outcomes for patients with BCR after RP.
Read More
NEPTUNES: Nivolumab, Ipilimumab for Metastatic Prostate Cancer With an Immunogenic Signature
Zachary Bessette
CRPC
|
June 4, 2024
Dr. Mark David Linch presented the results of NEPTUNES: a multicenter, 2-cohot, biomarker-selected, phase 2 trial.
Read More
CHAARTED2: Cabazitaxel Plus Abiraterone After Initial Docetaxel for mCRPC
Zachary Bessette
CRPC
|
June 3, 2024
Results from the CHAARTED2 trial was presented by Dr. Kyriakopoulos of the University of Wisconsin Carbone Cancer Center.
Read More
SURE-01/02: Perioperative Sacituzumab Govitecan for Patients With MIBC
Zachary Bessette
Muscle Invasive Urothelial Carcinoma
|
June 1, 2024
Neoadjuvant SG shows promising clinical activity in patients with MIBC and may help avoid radical cystectomy.
Read More
HERCULES: Pembrolizumab Plus Platinum-Based Chemotherapy for First-line Advanced Penile Cancer
Zachary Bessette
Testicular, Penile, and Rare Malignancies
|
May 31, 2024
A recent trial provides the first evidence of efficacy from ICIs in PSCC with a manageable safety profile.
Read More
NABUCCO Update: Efficacy, Biomarker Analysis of Preoperative Ipilimumab Plus Nivolumab
Zachary Bessette
Advanced Urothelial Carcinoma
|
May 31, 2024
An update on clinical efficacy and an exploratory biomarker analysis from the NABUCCO trial for patients with stage III UC.
Read More
First-line RCC Systemic Therapy Following Adjuvant Immunotherapy
Zachary Bessette
Advanced Renal Cell Carcinoma
|
June 10, 2024
Patients with RCC who experience disease recurrence after adjuvant IO benefit from subsequent systemic therapies.
Read More
High-Dose Chemotherapy Outcomes in Men With Germ Cell Cancer
Zachary Bessette
Testicular, Penile, and Rare Malignancies
|
May 31, 2024
The SWENOTECA cancer care program sought to evaluate survival, toxicity in patients treated with HDCT from 2011 through 2021.
Read More
EMBARK: Post Hoc Analysis of Impact of Treatment Suspension on HRQOL
Zachary Bessette
Localized
|
May 31, 2024
Researchers attempted to confirm whether treatment suspension for EMBARK patients may lead to improvements in HRQOL.
Read More
Analysis of the Cisplatin-Ineligible Population in EV-302
Zachary Bessette
Advanced Urothelial Carcinoma
|
May 30, 2024
Dr. van der Heijden presents a follow-up analysis of patients who were cisplatin-ineligible at randomization for EV-302.
Read More
KEYNOTE-361: Quantitative ctDNA Analysis in Patients With Advanced UC
Zachary Bessette
Advanced Urothelial Carcinoma
|
May 29, 2024
A retrospective analysis of ctDNA data by clinical outcomes with pembro vs chemotherapy for aUC from KEYNOTE-361.
Read More
Doublet Therapy Versus Monotherapy for Patients With Metastatic Chromophobe RCC
Zachary Bessette
nccRCC
|
June 7, 2024
Dr. Doshi and colleagues designed an analysis of patients with metastatic ChRCC to better understand first-line therapy.
Read More
Risk Score to Identify Optimal Patients for Adjuvant RT After Radical Prostatectomy
Zachary Bessette
Localized
|
May 6, 2024
Development of a novel risk score for early intensification approaches to RT or salvage RT for pN1 receiving RP.
Read More
TROP-2: Prognostic Significance for Penile Squamous Cell Carcinoma?
Zachary Bessette
Testicular, Penile, and Rare Malignancies
|
May 6, 2024
A study to determine the potential utility of ADCs targeting TROP-2 in both localized PSCC and distant metastases.
Read More
Neoadjuvant Versus Adjuvant Therapy for Clinical Node-Positive UTUC
Zachary Bessette
Upper Tract Urothelial Carcinoma
|
May 21, 2024
For patients with clinical node-positive UTUC, NAC may lead to improved outcomes compared with adjuvant chemotherapy.
Read More
IO Improves Survival for Patients With mRCC, Sarcomatoid Features After Cytoreductive Nephrectomy
Zachary Bessette
Advanced Renal Cell Carcinoma
|
May 4, 2024
ICIs improves OS for patients with mRCC and sarcomatoid features who undergo CN, regardless of the timing of surgery.
Read More
Radiation Therapy to Recurrence Sites for Patients Post-Radical Cystectomy
Zachary Bessette
Muscle Invasive Urothelial Carcinoma
|
May 3, 2024
RT to recurrence sites may not have an effect on oncologic outcomes in patients with MIBC after RC.
Read More
Intravesical Gemcitabine, Docetaxel for BCG-Naïve NMIBC
Zachary Bessette
Non-Muscle Invasive Urothelial Carcinoma
|
May 3, 2024
A phase 2 clinical trial assessed combination intravesical gemcitabine and docetaxel for BCG-naïve NMIBC.
Read More
Load More